Skip to main content
Erschienen in: International Urology and Nephrology 4/2008

01.12.2008 | Urology - Original Paper

Erectile dysfunction and Peyronie’s disease in patient with retroperitoenal fibrosis

verfasst von: Cem Akbal, Yılören Tanıdır, Mahir Bülent Özgen, Ferruh Şimşek

Erschienen in: International Urology and Nephrology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study is to determine the sexual dysfunction in patient with retroperitoneal fibrosis (RPF) and also we explored probability of Peyronie’s disease (PD) in this patient group and to compare this with the controls.

Materials and methods

Ten of 17 male RPF patients formed the basis of this study. Patient’s age, concomitant diseases were recorded. The diagnosis of PD was based on a palpable penile plaque or acquired penile curvature. Age-matched 88 patients who were admitted to our outpatient clinic with elevated PSA level served as the control group. All patients were asked to complete the IIEF-5 questionnaire. The severity of the erectile dysfunction (ED) was classified into four categories: severe (5–7), moderate (8–16), mild (17–21), and no ED (22–25). Concomitant systemic diseases were recorded. Statistical analyses were done by the Fisher’s exact test and an unpaired-sample t-test.

Results

Patients with severe ED or no sexual intercourse in the study group and the control group during the study period were found to be 7 and 14, respectively. The median IIEF-5 score in RPF patients and the control group was 9.8 (min: 5 to max: 23) and 19 (min: 5 to max: 25), respectively. The differences between groups were statistically significant (P = 0.002). In particular, ED was reported in eight RPF patients (80%) which was severe in six (60%) and moderate in two (20%). ED was reported in 45 patients in the control group (51%) which was severe in 14 (15.9%), mild in 25 (28.4%), and moderate in six (6.8%). Patients with RPF had a significant tendency for severe ED compared with the control group (P = 0.0042). Two patients in the RPF group (20%) and one patient in the control group (1.1%) were found to have a penile plaque (P = 0.0279). Relative risk for developing a penile plague was found to be 0.8 in RPF.

Conclusion

RPF patients are found to be more prone to developing ED. Penile plaque formation was identified in RPF patients, which may be presumed to relate to the pathological changes of the RPF process, but it remains unclear that these patients demonstrate a higher incidence of plaque formation than the normal population.

Literatur
  1. Debruyne FM, Bogman MJ, Ypma AF (1982) Retroperitoneal fibrosis in the scrotum. Eur Urol 8(1):45–48PubMed
  2. Buff DD, Bogin MB, Faltz LL (1989) Retroperitoneal fibrosis: report of selected cases and a review of the literature. N Y State J Med 89(9):511–516PubMed
  3. van Bommel EFH, van Spengler J, van der Hoven B et al (1991) Retroperitoneal fibrosis: report of 12 cases and review of the literature. Neth J Med 39:338–345PubMed
  4. Birnberg FA, Vinstein AL, Gorlick G et al (1982) Retroperitoneal fibrosis in children. Radiology 145:59–61PubMed
  5. Koep L, Zuidema GD (1977) The clinical significance of retroperitoneal fibrosis. Surgery 81:250–257PubMed
  6. Gilkeson GS, Allen NB (1996) Retroperitoneal fibrosis. A true connective tissue disease. Rheum Dis Clin North Am 22:23–38PubMedView Article
  7. Haag SM, Hauck EW, Szardening-Kirchner C et al (2007) Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie’s disease. Eur Urol 51(1):255–261PubMedView Article
  8. Wespes E, Amar E, Hatzichristou DG et al (2002) EAU guidelines on erectile dysfunction (Update March 2004). Eur Urol 41:1–5PubMedView Article
  9. Rosen RC, Cappelleri JC, Smith MD et al (1999) Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile function. Int J Impot Res 11:319–326PubMedView Article
  10. Bellastella A, Esposito D, Conte M et al (2005) Sexuality in aging male. J Endocrinol Invest 28(11):55–60PubMed
  11. Drieskens O, Blockmans D, van den Bruel A et al (2002) Riedel’s thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomography findings. Clin Nucl Med 27:413–415PubMedView Article
  12. Dehner LP, Coffin CM (1998) Idiopathic fibrosclerotic disorders and other inflammatory pseudotumors. Semin Diagn Pathol 15:161–173PubMed
  13. Hellstrom HR, Perez-Stable EC (1966) Retroperitoneal fibrosis with disseminated vasculitis and intrahepatic sclerosing cholangitis. Am J Med 40:184–187PubMedView Article
  14. Smith BH (1966) Peyronie’s disease. Amer J Clin Path 45:670–678PubMed
  15. Schwarzer U, Sommer F, Klotz T et al (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88:727–730PubMedView Article
  16. Kadioglu A, Oktar T, Kandirali E et al (2004) Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. Int J Impot Res 16:540–543PubMedView Article
  17. Kadioglu A, Tefekli A, Erol B et al (2002) A retrospective review of 307 men with Peyronie’s disease. J Urol 168(3):1075–1079PubMedView Article
  18. El-Sakka AI, Hassoba HW, Pillarisetty RJ (1997) Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 158:1391–1394PubMedView Article
  19. Anderson MS, Shankey TV, Lubrano T et al (2000) Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents. Int J Impot Res 12(Suppl 3):25–31View Article
  20. Somers KD, Dawson DM, Wright GL et al (1982) Cell culture of Peyronie’s disease plaque and normal penile tissue. J Urol 127(3):585–588PubMed
  21. Kanazawa S, Miyake T, Kakinuma T et al (2005) The expression of platelet-derived growth factor and connective tissue growth factor in different types of abdominal aortic aneurysms. J Cardiovasc Surg (Torino) 46(3):271–278
  22. Ramshaw AL, Roskell DE, Parums DV (1994) Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol 47(8):721–727PubMedView Article
  23. Moriya H, Ishida A, Nakabayashi I et al (1999) Juxtaglomerular cell tumor with retroperitoneal fibrosis and secondary immune-complex glomerulonephritis: a possible contribution of the renin angiotensin system to renal fibrosis. Am J Kidney Dis 34(3):10View Article
  24. Mulhall JP, Branch J, Lubrano T et al (2003) Radiation increases fibrogenic cytokine expression by Peyronie’s disease fibroblasts. J Urol 170(1):281–284PubMedView Article
  25. Whelan JS, Reznek R, Daniell SJN et al (1991) Computed tomography (CT) and ultrasound (US) guided core biopsy in the management of non-Hodgkin’s lymphoma. Br J Cancer 63(3):460–462PubMed
  26. Mitchinson MJ (1970) The pathology of idiopathic retroperitoneal fibrosis. J Clin Path 23:681–689PubMedView Article
  27. Akkus E, Carrier S, Baba K et al (1997) Structural alterations in the tunica albuginea of the penis: impact of Peyronie’s disease, ageing and impotence. Br J Urol 79:47–53PubMed
  28. El-Sakka AI (2006) Prevalence of Peyronie’s disease among patients with erectile dysfunction. Eur Urol 49(3):564–569PubMedView Article
Metadaten
Titel
Erectile dysfunction and Peyronie’s disease in patient with retroperitoenal fibrosis
verfasst von
Cem Akbal
Yılören Tanıdır
Mahir Bülent Özgen
Ferruh Şimşek
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2008
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9381-4

Weitere Artikel der Ausgabe 4/2008

International Urology and Nephrology 4/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.